Pharvaris’ (PHVS) “Buy” Rating Reiterated at HC Wainwright

Pharvaris (NASDAQ:PHVS)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $60.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 56.32% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research report on Friday, July 17th. New Street Research set a $60.00 price objective on shares of Pharvaris in a research note on Friday, August 14th. HSBC raised Pharvaris to an “overweight” rating in a research note on Thursday, August 13th. Wells Fargo & Company assumed coverage on Pharvaris in a research report on Wednesday, July 15th. They set an “overweight” rating and a $55.00 price target for the company. Finally, Royal Bank Of Canada boosted their target price on Pharvaris from $51.00 to $52.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $51.08.

Pharvaris Trading Up 8.9%

Shares of PHVS stock traded up $3.13 during trading hours on Tuesday, hitting $38.38. 3,774,112 shares of the company’s stock were exchanged, compared to its average volume of 358,838. The company has a market capitalization of $2.51 billion, a PE ratio of -12.63 and a beta of -2.33. The business’s 50 day simple moving average is $34.79 and its 200-day simple moving average is $31.12. Pharvaris has a 12-month low of $20.65 and a 12-month high of $43.25.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Equities analysts anticipate that Pharvaris will post -3.15 EPS for the current year.

Insider Buying and Selling at Pharvaris

In other news, Director Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the completion of the transaction, the director directly owned 315,167 shares in the company, valued at approximately $11,185,276.83. This trade represents a 8.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Berndt Modig sold 2,292 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $34.77, for a total value of $79,692.84. Following the completion of the sale, the chief executive officer owned 130,625 shares in the company, valued at $4,541,831.25. The trade was a 1.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 118,655 shares of company stock valued at $4,188,002.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PHVS. Quantbot Technologies LP purchased a new stake in shares of Pharvaris during the second quarter valued at approximately $41,000. CoreCap Advisors LLC bought a new stake in shares of Pharvaris during the second quarter valued at approximately $93,000. Barclays PLC purchased a new position in Pharvaris in the 4th quarter worth approximately $77,000. JPMorgan Chase & Co. raised its holdings in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the last quarter. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in Pharvaris in the 4th quarter valued at approximately $139,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.